Compare
Anixa Biosciences Inc vs Aprea Therapeutics, Inc. vs Reviva Pharmaceuticals Holdings, Inc. vs Aditxt, Inc.
| Latest fiscal year | Anixa Biosciences Inc ANIX | Aprea Therapeutics, Inc. APRE | Reviva Pharmaceuticals Holdings, Inc. RVPH | Aditxt, Inc. ADTX |
|---|---|---|---|---|
| Year ended | 2025-10-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | n/a | n/a | $3.2K |
| Revenue growth (YoY) | n/a | n/a | n/a | -97.6% |
| Gross margin | n/a | n/a | n/a | 8.4% |
| Operating margin | n/a | n/a | n/a | n/m |
| Net margin | n/a | n/a | n/a | n/m |
| Net income | -$10.93M | -$12.60M | -$19.86M | -$43.10M |
| EPS (Diluted) | -$0.34 | -$1.93 | n/a | -$1153.83 |
| Operating cash flow | -$7.17M | -$12.89M | -$24.59M | -$25.69M |
| Free cash flow | n/a | n/a | n/a | -$25.70M |
| Cash & equivalents | $1.24M | $14.60M | $14.44M | n/a |
| Total assets | $16.08M | $15.93M | $15.92M | $16.52M |
| Total liabilities | $2.13M | n/a | $7.28M | $12.56M |
| Shareholders' equity | $15.16M | $12.44M | $8.65M | $5.61M |
| Return on year-end equity | -72.1% | -101.3% | -229.7% | -768.3% |
| Shares outstanding | 33.01M | 8.19M | 5.87M | 411.5K |
Revenue, most recent five fiscal years
| Fiscal year | Anixa Biosciences Inc | Aprea Therapeutics, Inc. | Reviva Pharmaceuticals Holdings, Inc. | Aditxt, Inc. |
|---|---|---|---|---|
| Latest | $210.0K Ended 2024-10-31 | n/a | n/a | $3.2K Ended 2025-12-31 |
| 1 year earlier | $210.0K Ended 2023-10-31 | n/a | n/a | $134.0K Ended 2024-12-31 |
| 2 years earlier | n/a | n/a | n/a | $645.2K Ended 2023-12-31 |
| 3 years earlier | $512.0K Ended 2021-10-31 | n/a | n/a | $933.7K Ended 2022-12-31 |
| 4 years earlier | n/a | n/a | n/a | $105.0K Ended 2021-12-31 |